Consumption of added sugars (caloric sweeteners), which contribute calories but no other nutrients to the diet, are the source of more than one fifth of the calories consumed by US adolescents. The results of our study show that higher consumption of these sugars is associated with blood lipid levels that may place adolescents at increased risk of future cardiovascular disease. We also found that the risks associated with added sugar consumption may be higher among overweight or obese adolescents because higher consumption among this group was also associated with increased insulin resistance. Our findings highlight the prominence of added sugars in the diets of adolescents and suggest that reducing this consumption could be a strategy for modifying cardiovascular disease risk factors and helping to prevent cardiovascular disease. The associations demonstrated in our crosssectional study point to the need for controlled trials to determine if reducing consumption of added sugars can improve cardiovascular disease risk factors in adolescents and prevent future disease. See p 249.
Association of Maternal Diabetes Mellitus in Pregnancy With Offspring Adiposity Into Early Adulthood: Sibling Study in a Prospective Cohort of 280 866 Men From 248 293 Families
Maternal diabetes mellitus in pregnancy results in greater offspring adiposity at birth. However, it is unclear whether it results in greater adiposity into adulthood in humans. We undertook a large recordlinkage prospective-cohort study of 280 866 singleton-born Swedish men from 248 293 families in order to explore the intrauterine effect of maternal diabetes mellitus on offspring body mass index (BMI) in early adulthood. Maternal diabetes mellitus during pregnancy was associated with greater mean BMI at age 18 in their sons. The difference in BMI was similar within brothers and between unrelated individuals. BMI of men whose mothers had diabetes mellitus during their pregnancy was on average 0.94kg/m 2 greater (95% confidence interval, 0.35 to 1.52) than in their brothers born before their mother was diagnosed with diabetes. This association was independent of maternal early-pregnancy BMI. Our results show that maternal diabetes mellitus in pregnancy has long-term consequences that are, at least in part, driven by intrauterine mechanisms for greater BMI in offspring. These findings highlight the clinical importance of identifying and adequately treating gestational diabetes mellitus not only for the short-term health benefit of mother and baby, but also potentially for the longer-term prevention of obesity in offspring. See p 258.
Antihypertensive Treatment and Change in Blood Pressure Are Associated With the Progression of White Matter Lesion Volumes: The Three-City (3C)-Dijon Magnetic Resonance Imaging Study
Our study provides longitudinal population-based data on the relationship between blood pressure (BP) and cerebral white matter lesions (WMLs) in the elderly. WMLs are frequent in older individuals, and there is increasing evidence that they could be a marker of the risk of future stroke or dementia. In cross-sectional studies, elevated BP consistently relates to WMLs, but the relationship of baseline BP and changes in BP to the development of WML over time is less certain. In a longitudinal population-based study including 1319 subjects 65 to 80 years of age, we found that both baseline BP levels and change in BP levels over a 4-year follow-up were significantly associated with higher WML volume progression over 4 years. In addition, our data suggest that antihypertensive therapy was associated with a slowed progression of WML in individuals with high BP and untreated at study entry. Clinical trials are needed to determine whether white matter abnormalities are prevented or progression is slowed by antihypertensive therapy and serve as an early marker of successful treatment. Trials could also determine whether preventing WMLs with antihypertensive treatment can reduce the risk of dementia, which is an important goal in many increasingly older populations. See p 266.
Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction: Optical Coherence Tomography Substudy of the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial
Pathological studies have demonstrated an association between uncovered struts in drug-eluting stents and subsequent stent thrombosis. Drug-eluting stent implantation in ST-elevation myocardial infarction may further impair stent strut endothelialization. Optical coherence tomography (OCT) can measure stent strut coverage in vivo with a high level of accuracy. We therefore used OCT at 13 month follow-up to examine the completeness of strut coverage and local vascular response to TAXUS Express paclitaxel-eluting stents (PES) compared with Express bare-metal stent (BMS) implanted in ST-elevation myocardial infarction. This hypothesis was tested in a formal OCT substudy as part of the large-scale, prospective, randomized Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) trial. The primary prespecified endpoint, the percentage of uncovered stent struts per lesion at follow-up, occurred in 1.1%Ϯ2.5% struts per BMS lesion versus 5.7%Ϯ7.0% struts per PES lesion (PϽ0.0001). Malapposed struts were observed in 0.1%Ϯ0.2% struts per BMS lesion
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Original Research Put Into Perspective for the Practicing Clinician Volume 123 Ⅲ Number 3 Ⅲ January 25, 2011 versus 0.9%Ϯ2.1% struts per PES lesion (Pϭ0.0003). Percent net volume obstruction was 36%Ϯ15.4% with BMS and 19.2%Ϯ11.3% with PES (PϽ0.0001). In patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention, implantation of PES as compared with BMS significantly reduces neointimal hyperplasia, but results in higher rates of uncovered and malapposed stent struts as assessed by OCT at 13-month follow-up. Ongoing studies are required to determine the relationship between these OCT observations and long-term adverse clinical events. See p 274.
Deregulation of microRNA-503 Contributes to Diabetes Mellitus-Induced Impairment of Endothelial Function and Reparative Angiogenesis After Limb Ischemia
MicroRNAs (miRNAs) are post-transcriptional inhibitory regulators of gene expression that bind to complementary messenger RNA transcripts. After initial studies in developmental biology and cancer, miRNAs have recently come into focus of cardiovascular diagnostics and therapeutics. Because each miRNA can repress many target mRNAs, it is possible that dysregulation of a single miRNA might account, at least in part, for complex pathological situations. Here, we report for the first time the importance of miR-503 in diabetes mellitus-associated ischemic disease, which currently represents a major cause of morbidity and mortality in diabetic patients. In vitro, the combination of high glucose and starvation remarkably enhances the expression of miR-503 in human endothelial cells, and so does diabetes mellitus in endothelial cells extracted from murine ischemic limb muscles. In vitro experiments showed that forced expression of miR-503 inhibits endothelial cell proliferation and endothelial network formation. Because miR-503 represses cell cycle-associated genes, we investigated whether miR-503 activation may impinge on postischemic reparative angiogenesis. In a diabetic mouse model of limb ischemia, local inhibition of miR-503 activity accelerated vascular healing and blood flow recovery. Importantly, miR-503 was found up-regulated in muscular biopsies and peripheral bloodderived plasma of diabetic patients with critical limb ischemia. From a therapeutic perspective, manipulation of miR-503 may represent a novel molecular means to foster reparative angiogenesis in diabetic patients. In the diagnostic context, more studies are necessary to determine if miR-503 could be exploited as a biomarker of progressive vascular disease. See p 282.
Determinants of Blood Pressure in Preschool Children: The Role of Parental Smoking
There is increasing evidence that environmental tobacco exposure has significant effects on cardiovascular health even at a young age. Abnormal arterial morphology and function have been demonstrated in teenagers exposed to second-hand smoking. The age at which cardiovascular effects of passive smoking first become detectable has not been established to date. This population-based study was designed to explore endogenous and exogenous determinants of blood pressure (BP) in preschool children. BP was measured in conjunction with a family health and lifestyle survey in a cohort of 4236 children aged 4 to 6 years. Multifactorial dependency of BP on body stature and familial, prenatal, and environmental influences was observed. Among these factors, exposure to parental smoking was associated with a small but consistent BP-raising effect, which remained significant when adjusted for numerous potentially collinear anthropometric, medical, and social factors affecting BP in the children and their parents, including prenatal conditions. Childhood BP was quantitatively correlated with the daily cigarette consumption of the mothers only, compatible with closer exposure to maternal smoking at home. The findings of this study add an important pediatric perspective to the issue of prevention and containment of active and passive smoking. They complete the picture of tobacco exposure interfering with cardiovascular maturation and health from gestation to adulthood. The benefit of successful primary prevention programs would most likely not be limited to adults but extend even to the youngest family members. See p 292.
Incidence and Predictors of Early and Late Mortality After Transcatheter Aortic Valve Implantation in 663 Patients With Severe Aortic Stenosis
Transcatheter aortic valve implantation using the self-expandable CoreValve prosthesis was performed in 663 patients with severe aortic stenosis and high surgical risk in 14 Italian centers. Procedural success was 98% and intraprocedural mortality was 0.9%. The mortality rates at 30 days and 1 year were 5.4% and 15.0%, respectively. Early mortality was acceptably low compared with the anticipated risk calculated by means of the EuroSCORE and was strongly associated with the occurrence of procedural complications. Late mortality continued to occur from 30 days to 1 year after TAVI, primarily as the effect of postprocedural paravalvular aortic regurgitation Ն2ϩ and nonvalve related comorbidities such as cerebrovascular disease, chronic kidney disease and heart failure. Clinical and hemodynamic benefits observed acutely after TAVI were sustained at 1 year. See p 299.
Blocking the NOTCH Pathway Inhibits Vascular Inflammation in Large-Vessel Vasculitis
Giant cell arteritis (formerly called temporal arteritis) is an inflammatory vasculopathy that causes aortic wall damage and lumenstenosing lesions in medium-sized arteries. Giant cell arteritis preferentially targets extracranial branches of the aorta, resulting in ischemic optic neuropathy, stroke, pulselessness, and aortic aneurysm/dissection. If diagnosed and treated promptly, ischemic organ damage such as blindness can be prevented. The standard of care involves high doses of corticosteroids, often given over prolonged periods. Alternative treatment approaches are urgently needed. A critical step in the disease process is the activation of proinflammatory T cells in the vessel wall. Here, we searched for receptor-ligand pairs relevant in T-cell activation, with the ultimate goal of developing novel antiinflammatory interventions. We found that vascular lesions of giant cell arteritis patients abundantly expressed NOTCH and NOTCH ligands and accumulated NOTCH1 ϩ T cells. The NOTCH signaling pathway has mostly been recognized for its role in determining cell fate, especially during development and tissue homeostasis. NOTCH pathway signaling depends on 2 proteolytic cleavage processes, including the action of a ␥-secretase, which can be inhibited by an enzyme blocker. Treatment with the ␥-secretase inhibitor or alternatively a soluble NOTCH ligand effectively suppressed vascular inflammation in a humanized mouse model. NOTCH signaling blockade suppressed activity of interferon-␥producing Th1 cells and almost depleted interleukin-17-producing Th17 cells. Targeting the NOTCH-NOTCH ligand pathway may provide a novel strategy to suppress the activity of vasculitic T cells in large and medium vessel vasculitis. See p 309.
Humanized Mouse Model of Thrombosis Is Predictive of the Clinical Efficacy of Antiplatelet Agents
Platelet adhesion and activation are key events contributing to arterial thrombosis in disease states such as atherosclerosis, the leading cause of morbidity and mortality in industrialized countries. Although our current therapeutic armamentarium for preventing and treating complications associated with atherothrombosis has yielded promising results, there remains an urgent need for more effective drugs and better monitoring of treatment modalities. To expedite this process, it is necessary to develop animal models that more accurately recapitulate the human response to antiplatelet agents. In the present report, we demonstrate how mice bearing a genetically modified form of VWF can serve as a biological platform for predicting the in vivo efficacy of such therapies by enabling human platelet thrombus formation at sites of vascular injury, an event critically reliant on adhesion receptors, secretory products, and activation pathways known to contribute to this process in atherosclerotic coronary arteries (ie, ␣IIb␤3, ADP, and P2Y 12 ). This is further supported by the ability of the Food and Drug Administration-approved ␣IIb␤3 blockers abciximab, eptifibatide, and tirofiban to effectively limit human but not mouse platelet-mediated clot formation at doses recommended by the American College of Cardiology/American Heart Association for percutaneous coronary intervention. However, the most beneficial aspect of this model may be its ability to ascertain the inhibitory capacity of antiplatelet agents after administration to patients. As such, it may aid in correlating values obtained by function monitoring devices with the thrombogenic capacity of platelets when exposed to sites of vascular damage in a living animal, thus providing new insights into this highly debated area of clinical research. See p 319.
